Regulus Therapeutics has partnered up with Biogen Idec to identify microRNA biomarkers in the blood of patients with multiple sclerosis, and the California biotech has charted some progress, pocketing a milestone payment and moving toward companion diagnostic development.
Regulus Therapeutics, a biotech using microRNA as a target for drug delivery, raised nearly $49 million through a public offering completed Tuesday, up from an anticipated $43 million.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
It may not have been pretty, but Regulus Therapeutics raised close to $81 million from its recent IPO and some related transactions.
It may not have been pretty, but Regulus Therapeutics ($RGLS) raised close to $81 million from its recent IPO and some related transactions. And they did it with a big assist from some major league partners in the biopharma industry.
After taking a beating in previous years, biotech has been hot sector on Wall Street this year. The Nasdaq Biotech Index has shot up 30% this year compared with 15% growth in the broader market. And the fact that this year's total number of biotech IPOs already matches that of 2011 indicates that there could be a growing appetite for these types of investments. But there's no indication that we're on the verge of, or will ever, return to the go-go years of the 1990s when biotechs more easily went public at lofty values. Here's the full report >>
Regulus Therapeutics capped a busy week of deal-making with a proposed initial public offering of $57.5 million, which the biotech would use in part to fund work on its pipeline of microRNA drugs now in pre-clinical development for cancer, hepatitis C, cardiovascular and fibrotic diseases.
Regulus Therapeutics has signed a deal to lend its microRNA knowhow to Biogen Idec, looking to develop diagnostics for multiple sclerosis.
Regulus Therapeutics will take in $28 million as part of a new partnership with AstraZeneca ($AZN) involving preclinical work on metabolic diseases, cancer and antherosclerosis.
Regulus Therapeutics has signed up another Big Pharma player to its roster of marquee microRNA partners. AstraZeneca will fork over $28 million in equity and an upfront fee to collaborate on three targets, including a lead program that will be explored for its potential to treat atherosclerosis.